As PRMT5-mediated FUBP1 methylation is not limited to prostate cancer, the clinical application of this competitive peptide may extend to other cancers, and HA/BPAE/peptide NCs could be used to treat various cancers with reduced systemic side effects and improved therapeutic efficacy. This evidence concerns the gene PRMT5 and prostate carcinoma.